These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 28503960)

  • 21. Efficacy of TNFα inhibitors for refractory vascular Behçet's disease: A multicenter observational study of 27 patients and a review of the literature.
    Aksoy A; Yazici A; Omma A; Cefle A; Onen F; Tasdemir U; Ergun T; Direskeneli H; Alibaz-Oner F
    Int J Rheum Dis; 2020 Feb; 23(2):256-261. PubMed ID: 31976619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intestinal Behçet's disease: maintenance of remission with adalimumab monotherapy.
    Ariyachaipanich A; Berkelhammer C; Nicola H
    Inflamm Bowel Dis; 2009 Dec; 15(12):1769-71. PubMed ID: 19177427
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients.
    Fabiani C; Vitale A; Rigante D; Emmi G; Bitossi A; Lopalco G; Sota J; Guerriero S; Orlando I; Gentileschi S; Iannone F; Frediani B; Galeazzi M; Vannozzi L; Tosi GM; Cantarini L
    Clin Rheumatol; 2019 Feb; 38(2):407-415. PubMed ID: 30099655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful treatment of life-threatening intestinal ulcer in Behçet's disease with infliximab: rapid healing of Behçet's ulcer with infliximab.
    Ju JH; Kwok SK; Seo SH; Yoon CH; Kim HY; Park SH
    Clin Rheumatol; 2007 Aug; 26(8):1383-5. PubMed ID: 17039261
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab.
    Olivieri I; Leccese P; D'Angelo S; Padula A; Nigro A; Palazzi C; Coniglio G; Latanza L
    Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S54-7. PubMed ID: 21968237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An incomplete form of childhood Behçet's disease treated with infliximab.
    Caporuscio S; Pranteda G; Nistico S; Maucione T; Canzoni M; Stefani A; Muscianese M; Fanto M; Sorgi M
    Int J Immunopathol Pharmacol; 2014; 27(3):445-8. PubMed ID: 25280037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients.
    Barroso-García N; Atienza-Mateo B; Ferraz-Amaro I; Prieto-Peña D; Beltrán E; Adán A; Hernández-Garfella M; Martínez-Costa L; Cordero-Coma M; Díaz-Llopis M; Herreras JM; Maíz-Alonso O; Torre-Salaberri I; De Vicente-Delmás A; Díaz-Valle D; Atanes-Sandoval A; Francisco F; Insua S; Sánchez J; Almodóvar-González R; Jiménez-Sosa A; Ruiz-Moreno O; Gandía-Martínez M; Nolla JM; Calvo-Río V; Castañeda S; González-Gay MA; Blanco R
    Semin Arthritis Rheum; 2023 Feb; 58():152153. PubMed ID: 36549244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful Treatment with Adalimumab for Intestinal Behcet's Disease during Pregnancy.
    Fujikawa K; Endo Y; Mizokami A; Takahashi K; Tabuchi M; Ohba K; Nakamura H; Kawakami A
    Intern Med; 2016; 55(10):1375-8. PubMed ID: 27181551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update on the Treatment of Behcet's Disease of the Small Bowel with Biologic Agents.
    Park Y; Cheon JH
    Curr Gastroenterol Rep; 2020 Mar; 22(5):24. PubMed ID: 32193746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Behçet's disease; A rare refractory patient with vena cava superior syndrome treated with infliximab: a case report and review of the literature.
    Uyaroglu OA; Erden A; Kilic L; Peynircioğlu B; Karadag O; Kalyoncu U
    Acta Clin Belg; 2019 Oct; 74(5):364-369. PubMed ID: 30220250
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease.
    Iwata S; Saito K; Yamaoka K; Tsujimura S; Nawata M; Hanami K; Tanaka Y
    Mod Rheumatol; 2011 Apr; 21(2):184-91. PubMed ID: 21052764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pulmonary artery aneurysms in Behçet's disease treated with anti-TNFα: A case series and review of the literature.
    Chan E; Sangle SR; Coghlan JG; D'Cruz DD
    Autoimmun Rev; 2016 Apr; 15(4):375-8. PubMed ID: 26777307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adalimumab for sight-threatening uveitis in Behçet's disease.
    Mushtaq B; Saeed T; Situnayake RD; Murray PI
    Eye (Lond); 2007 Jun; 21(6):824-5. PubMed ID: 16601736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and predictor of anti-TNFα agents in patients with intestinal Behçet's disease.
    Miyazaki H; Watanabe D; Okamoto N; Tokunaga E; Ku Y; Takenaka H; Hoshi N; Ooi M; Kodama Y
    BMC Gastroenterol; 2022 Mar; 22(1):149. PubMed ID: 35346067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
    Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
    Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Updated treatment strategies for intestinal Behçet's disease.
    Park YE; Cheon JH
    Korean J Intern Med; 2018 Jan; 33(1):1-19. PubMed ID: 29207867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis.
    Ohno S; Nakamura S; Hori S; Shimakawa M; Kawashima H; Mochizuki M; Sugita S; Ueno S; Yoshizaki K; Inaba G
    J Rheumatol; 2004 Jul; 31(7):1362-8. PubMed ID: 15229958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-TNF-α Therapy for Refractory Uveitis Associated with Behçet's Syndrome and Sarcoidosis: A Single Center Study of 131 Patients.
    Kunimi K; Usui Y; Asakage M; Maehara C; Tsubota K; Mitsuhashi R; Umazume A; Kezuka T; Sakai JI; Goto H
    Ocul Immunol Inflamm; 2022 Jan; 30(1):223-230. PubMed ID: 32815752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report.
    Gulli S; Arrigo C; Bocchino L; Morgante L; Sangari D; Castagna I; Bagnato GF
    BMC Musculoskelet Disord; 2003 Aug; 4():19. PubMed ID: 12946278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The safety and efficacy of TNF inhibitors in patients with Behçet's disease: Retrospective study from eastern Turkey.
    Bektaş M; Özer MD; Oğuz E
    Clin Immunol; 2024 Jul; 264():110239. PubMed ID: 38734038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.